Sökning: id:"swepub:oai:gup.ub.gu.se/299095" >
Autologous haematop...
Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing-remitting multiple sclerosis: An observational study
-
- Zhukovsky, Christina (författare)
- Uppsala universitet,Landtblom: Neurovetenskap
-
- Sandgren, Sofia, 1983 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för klinisk neurovetenskap,Institute of Neuroscience and Physiology, Department of Clinical Neuroscience,Sahlgrens Acad, Inst Neurosci & Physiol, Dept Clin Neurosci, Gothenburg, Sweden.
-
- Silfverberg, Thomas (författare)
- Uppsala universitet,Hematologi,Centrum för klinisk forskning Dalarna
-
visa fler...
-
- Einarsdottir, Sigrun (författare)
- Sahlgrens Univ Hosp, Dept Hematol & Coagulat, Gothenburg, Sweden.
-
- Tolf, Andreas (författare)
- Uppsala universitet,Landtblom: Neurovetenskap
-
- Landtblom, Anne-Marie (författare)
- Uppsala universitet,Landtblom: Neurovetenskap
-
- Novakova, Lenka, 1984 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för klinisk neurovetenskap,Institute of Neuroscience and Physiology, Department of Clinical Neuroscience,Sahlgrens Acad, Inst Neurosci & Physiol, Dept Clin Neurosci, Gothenburg, Sweden.
-
- Axelsson, Markus, 1975 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för klinisk neurovetenskap,Institute of Neuroscience and Physiology, Department of Clinical Neuroscience,Sahlgrens Acad, Inst Neurosci & Physiol, Dept Clin Neurosci, Gothenburg, Sweden.
-
- Malmeström, Clas, 1965 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för klinisk neurovetenskap,Institute of Neuroscience and Physiology, Department of Clinical Neuroscience,Sahlgrens Acad, Inst Neurosci & Physiol, Dept Clin Neurosci, Gothenburg, Sweden.
-
- Cherif, Honar (författare)
- Uppsala universitet,Hematologi
-
- Carlson, Kristina (författare)
- Uppsala universitet,Hematologi
-
- Lycke, Jan, 1956 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för klinisk neurovetenskap,Institute of Neuroscience and Physiology, Department of Clinical Neuroscience,Sahlgrens Acad, Inst Neurosci & Physiol, Dept Clin Neurosci, Gothenburg, Sweden.
-
- Burman, Joachim, 1974- (författare)
- Uppsala universitet,Landtblom: Neurovetenskap
-
visa färre...
-
(creator_code:org_t)
- 2020-10-26
- 2021
- Engelska.
-
Ingår i: Journal of Neurology, Neurosurgery and Psychiatry. - : BMJ. - 0022-3050 .- 1468-330X. ; 92:2, s. 189-194
- Relaterad länk:
-
https://jnnp.bmj.com...
-
visa fler...
-
https://doi.org/10.1...
-
https://uu.diva-port... (primary) (Raw object)
-
https://gup.ub.gu.se...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. Objective: To compare outcomes after treatment with autologous haematopoietic stem cell transplantation (AHSCT) and alemtuzumab (ALZ) in patients with relapsing-remitting multiple sclerosis. Methods: Patients treated with AHSCT (n=69) received a conditioning regimen of cyclophosphamide (200 mg/kg) and rabbit anti-thymocyte globulinerG (6.0 mg/kg). Patients treated with ALZ (n=75) received a dose of 60 mg over 5 days, a repeated dose of 36 mg over 3 days after 1 year and then as needed. Follow-up visits with assessment of the expanded disability status scale score, adverse events and MR investigations were made at least yearly. Results: The Kaplan-Meier estimates of the primary outcome measure 'no evidence of disease activity' was 88% for AHSCT and 37% for ALZ at 3 years, p<0.0001. The secondary endpoint of annualised relapse rate was 0.04 for AHSCT and 0.1 for ALZ, p=0.03. At last follow-up, the proportions of patients who improved, were stable or worsened were 57%/41%/1% (AHSCT) and 45%/43%/12% (ALZ), p=0.06 Adverse events grade three or higher were present in 48/69 patients treated with AHSCT and 0/75 treated with ALZ in the first 100 days after treatment initiation. The most common long-term adverse event was thyroid disease with Kaplan-Meier estimates at 3 years of 21% for AHSCT and 46% for ALZ, p=0.005. Conclusions: In this observational cohort study, treatment with AHSCT was associated with a higher likelihood of maintaining 'no evidence of disease activity'. Adverse events were more frequent with AHSCT in the first 100 days, but thereafter more common in patients treated with ALZ.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Neurologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Neurology (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Zhukovsky, Chris ...
-
Sandgren, Sofia, ...
-
Silfverberg, Tho ...
-
Einarsdottir, Si ...
-
Tolf, Andreas
-
Landtblom, Anne- ...
-
visa fler...
-
Novakova, Lenka, ...
-
Axelsson, Markus ...
-
Malmeström, Clas ...
-
Cherif, Honar
-
Carlson, Kristin ...
-
Lycke, Jan, 1956
-
Burman, Joachim, ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Neurologi
- Artiklar i publikationen
-
Journal of Neuro ...
- Av lärosätet
-
Göteborgs universitet
-
Uppsala universitet